Ignite Creation Date:
2025-12-25 @ 2:07 AM
Ignite Modification Date:
2026-04-26 @ 9:10 AM
Study NCT ID:
NCT04181060
Status:
RECRUITING
Last Update Posted:
2025-12-24
First Post:
2019-11-27
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Sponsor:
National Cancer Institute (NCI)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-12-28
Start Date Type:
ACTUAL
Primary Completion Date:
2026-12-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2019-11-27
First Submit QC Date:
None
Study First Post Date:
2019-11-29
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-23
Last Update Post Date:
2025-12-24
Last Update Post Date Type:
ACTUAL